AUPH news

Latest 3 stories · newest Oct 30, 2026

AUPH

Aurinia reports Q3 2026 revenue of $83.7M, raising 2026 guidance to $325M-$330M

Aurinia Pharmaceuticals boosted its 2026 revenue guidance as Q3 net product sales of LUPKYNIS rose 12% and total revenue climbed 14%. The company reported Q3 cash balances of $486.9 million.

Earnings|Guidance Oct 30, 2026 sentiment +0.50 SEC filing ↗

AUPH

Aurinia Q2 Beat with Revenue, Net Income Jump 21% and 60%

Aurinia Pharmaceuticals reported strong Q2 earnings with 21% revenue growth and a 60% increase in net income. The company also provided updated 2026 guidance.

Earnings Aug 6, 2026 sentiment 0.00 SEC filing ↗

AUPH

10 Health Care Stocks Whale Activity In Today's Session

Options Jun 5, 2026 sentiment 0.00 Source: benzinga.com ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same AUPH feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/AUPH/newsSTART FREE